What question did this study set out to answer?

To evaluate the 20-year pricing trajectories of disease-modifying therapies for multiple sclerosis in the United States and identify market factors influencing price escalation.

April 25, 2015NeurologyOpen Access

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry

View Full Paper

Ask AI

Bookmark

Authors

DHDaniel M. HartungOregon State University DBDennis BourdetteOregon Health & Science University SASharia M. AhmedEmory University

Discussion

Member takes

Implication

Economic analysis shows multiple sclerosis drug prices increased substantially faster than prescription inflation in the United States, highlighting an urgent need for market reform.

Key Points

To evaluate the 20-year pricing trajectories of disease-modifying therapies for multiple sclerosis in the United States and identify market factors influencing price escalation.
Analyzed published pricing data from 1993 to 2013 across 9 disease-modifying therapies (DMTs) for multiple sclerosis.
Compared DMT cost trends to general inflation, prescription drug inflation, and cost trajectories of contemporaneously approved biologic tumor necrosis factor (TNF) inhibitors.
Annual costs for first-generation DMTs increased from $8,000–$11,000 to approximately $60,000 per year, rising 5 to 7 times faster than general prescription drug inflation.
Newer DMTs entered the market at prices 25% to 60% higher than existing agents, triggering sharp price increases in older first-generation drugs following the introduction of agents like natalizumab and fingolimod.
Current multiple sclerosis DMT prices in the United States are 2 to 3 times higher than those observed in other comparable countries.

Cite This Study

Hartung et al. (2015) studied this question.

synapsesocial.com/papers/6a770340a0847c3df1ec4bef https://doi.org/10.1212/wnl.0000000000001608

View Full Paper

Ask AI

Bookmark

Implication

Economic analysis shows multiple sclerosis drug prices increased substantially faster than prescription inflation in the United States, highlighting an urgent need for market reform.

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry

Discussion

Member takes

Implication

Key Points

Cite This Study

The cost of multiple sclerosis drugs in the US and the pharmaceutical industry

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider